Maintenance chemotherapy in non-small cell lung cancer

Annals of Oncology

Volumn 17, Issue SUPPL. 2, 2006, Pages

  Rinaldi, M ^a   Belvedere, O ^b   Cauchi, C ^a   Defferrari, C ^c   Viola, G ^a   Grossi, F ^c  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY HOSPITAL OF UDINE   (Italy)

^c UNIVERSITY OF GENOA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ALPHA2A INTERFERON; BEXAROTENE; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; GEFITINIB; GEMCITABINE; LOMUSTINE; METHOTREXATE; MITOMYCIN; NAVELBINE; PACLITAXEL; PEMETREXED; PLACEBO; UFT; VINBLASTINE;

ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER GROWTH; CANCER SURVIVAL; CELL KILLING; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; DRUG SUBSTITUTION; FEASIBILITY STUDY; HUMAN; LOW DRUG DOSE; LUNG NON SMALL CELL CANCER; MAINTENANCE THERAPY; NEUROPATHY; OVERALL SURVIVAL; PRIORITY JOURNAL; QUALITY OF LIFE; SURVIVAL RATE; SURVIVAL TIME; SYMPTOMATOLOGY; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 33645803198     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdj928     Document Type: Article

References (21)

1. Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials. Br Med J 1995; 311: 899-909.
2. American Society of Clinical Oncology. Clinical practice guidelines for the treatment of unresectable non-small cell lung cancer. J Clin Oncol 1997; 15: 2996-3018.
3. Buccheri GF, Ferrigno D, Curcio A et al. Continuation of chemotherapy vs supportive care alone in patients with inoperable non-small cell lung cancer and stable disease after two or three cycles of MACC. Cancer 1989; 63: 428-432.
4. Smith IE, O'Brien MER, Talbot DC et al. Duration of chemotherapy in advanced non-small cell lung cancer: A randomized trial of three vs six courses of mitomycin, vinblastin, and cisplatin. J Clin Oncol 2001; 19: 1336-1343.
5. Socinski MA, Scell MJ, Peterman A et al. A phase III trial comparing a defined duration of therapy vs continuous therapy followed by second-line tharapy in advanced stage IIIB/IV non-small cell lung cancer. J Clin Oncol 2002; 20: 1335-1343.
6. Pfister DG, Johnson DH, Azzoli CG et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 2004; 22: 330-353.
7. Andresen O, Sorenson S, Bergman B et al. Duration of chemotherapy and survival in advanced non-small cell lung cancer (NSCLC). A multicenter, prospective randomised study. Lung Cancer 2003; 41: S28.
8. Goldie JH, Coldman AJ, Gudauskas GA. Rationale for the use of alternating non-cross-resistant chemotherapy. Cancer Treat Rep 1982; 66: 439-449.
9. Day RS. Treatment sequencing, asymmetry, and uncertainty: Protocol strategies for combination chemotherapy. Cancer Res 1986; 46: 3876-85.
10. Westeel V, Quoix E, Moro-Sibilot D et al. Randomized study of maintenance vinorelbine in responders with advanced non-small cell lung cancer. J Natl Cancer Inst 2005; 97: 499-506.
11. Belani CP, Barstis J, Perry MC et al. Multicenter, randomized trial for stage IIIB or IV non-small-cell lung cancer using weekly paclitaxel and carboplatin followed by maintenance weekly paclitaxel or observation. J Clin Oncol 2003; 21: 2933-2939.
12. Belani CP, Perry MC, La Rocca RV et al. Maintenance therapy (MT) with weekly paclitaxel improves outcome for advanced non-small cell lung cancer (NSCLC) patients. Proc Am Soc Clin Oncol 2005; 23: (Abstr 7143).
13. Krzakowski M, Wenkzl M, Brodowicz T et al. Gemcitabine and cisplatin +/- subsequent maintenance therapy with single-agent gemcitaibine in advanced non-small cell lung cancer (NSCLC): Preliminary results of a randomized trial of the Central European Cooperative Oncology Group (CECOG). Proc Am Soc Clin Oncol 2004; 23: (Abstr 7067).
14. Rinaldi M, Novello S, Falcone A et al. Preliminary results of a multicenter randomized phase II trial of two different combinations of docetaxel (D) and gemcitabine (G) and of cisplatin/gemcitabine (CG) followed by docetaxel as first line therapy for locally advanced or metastatic non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2005; 23: (Abstr 7124).
15. Novello S, Bruzzi P, Barone C et al. Phase III study in stage IV non-small cell lung cancer (NSCLC) patients (pts) treated with two cycles of cisplatin/gemcitabine followed by a randomization to three additional cycles of the same combination or gemcitabine alone. Proc Am Soc Clin Oncol 2005; 23: (Abstr 7051).
16. Gandara DR, Chansky K, Gaspar LE et al. Long term survival in stage IIIb non-small cell lung cancer (NSCLC) treated with consolidation docetaxel following concurrent chemoradiotherapy (SWOG S9504). Proc Am Soc Clin Oncol 2005; 23: (Abstr 7059).
17. Sekine I, Nokihara H, Sumi M et al. Docetaxel (D) consolidation therapy following cisplatin (P), vinorelbine (V) and concurrent thoracic radiotherapy (TRT) in patients with unresectable stage III non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2005; 23: (Abstr 7125).
18. Kataja V, Yap A. Combination of cisplatin and interferon-alpha 2a (Roferon-A) in patients with non-small cell lung cancer (NSCLC). An open phase II multicentre study. Eur J Cancer 1995; 31A: 35-40.
19. Prior C, Oroszy S, Oberaigner W et al. Advanced non-small-cell lung cancer: Adjunctive interferon α in induction and maintenance therapy. J Cancer Res Clin Oncol 1999; 125: 42-46.
20. Rizvi N, HawKins MJ, Eisenberg PO et al. Placebo-controlled trial of bexarotene, a retinoid x receptor agonist, as maintenance therapy for patients treated with chemotherapy for advanced non-small-cell lung cancer, Clin Lung Cancer 2001; 2: 210-215.
21. Marsland TA, Garfield DH, Khan MM et al. Phase II study of sequential chemotherapy followed by oral maintenance therapy with Orzel (UFT + leucovorin) in patients (pts) with stage IIIB and IV non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2002; 21: (Abstr 2745).